Evidence map›Paper›PMID 36852998›Full record

Trial reportAntimicrobial agents and chemotherapy2023

Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study.

Sean T H Liu, Mila Mirceta, Grace Lin, Deborah M Anderson, Tarashon Broomes, Alina Jen, Ashley Abid, David Reich, Christine Hall, Judith A Aberg

Open access · hybridFull text readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Latest Findings in Immunoglobulin Y Technologies and Applications.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Sean T H LiuDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-3842-6838
Mila MircetaEmergent BioSolutions Canada, Inc., Winnipeg, Manitoba, Canada.
Grace LinEmergent BioSolutions Canada, Inc., Winnipeg, Manitoba, Canada.
Deborah M AndersonEmergent BioSolutions Canada, Inc., Winnipeg, Manitoba, Canada.
Tarashon BroomesDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Alina JenDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Ashley AbidDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
David ReichDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Christine HallEmergent BioSolutions Canada, Inc., Winnipeg, Manitoba, Canada.
Judith A AbergDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0001-8162-0284
Icahn School of Medicine at Mount Sinai · USEmergent BioSolutions (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-SARS-CoV-2 immunoglobulin (human) investigational product (COVID-HIGIV) is a purified immunoglobulin preparation containing SARS-CoV-2 polyclonal antibodies. This single-center clinical trial aimed to characterize the safety and pharmacokinetics of COVID-HIGIV in healthy, adult volunteers. Participants were enrolled to receive one of three doses of COVID-HIGIV (100, 200, 400 mg/kg) or placebo in a 2:2:2:1 randomization scheme. Between 24 December 2020 and 27 July 2021, 28 participants met eligibility and were randomized with 27 of these 28 (96.4%) being administered either COVID-HIGIV (

Indexed as

COVID-19Administration, IntravenousAdultAntibodies, ViralDouble-Blind MethodHumansImmunoglobulin GSARS-CoV-2Antibodies, ViralImmunoglobulin Gantiviral pharmacologyCOVID-19hyperimmune immunoglobulin

Identifiers

PMID36852998
PMCPMC10019156
OpenAlexW4322617370

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read85
identifiers read1
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.